Understanding MET in NSCLC
Disease Education
Discover IL-1β Inhibition, Immunotherapy, and Targeted Therapy in Lung Cancer
Targeting KRAS & SHP2 Mechanism of Action
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
MOA data are based on in vitro/in vivo data.
Explore Clinical Trials
Explore Clinical Trials
2L+
KontRASt-01
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
2L+
KontRASt-02
A randomized, controlled, open-label, Phase III study evaluating the efficacy and safety of JDQ443 vs docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC)
2L+
KontRASt-03
A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation
1L
KontRASt-06
An open-label Phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC) with a PD-L1 expression <1% or a PD-L1 expression ≥1% and an STK11 co-mutation
IAG933
A Phase I, open-label, multicenter study to evaluate the safety and tolerability, and identify the recommended dose (RD) or maximum tolerated dose (MTD) of oral IAG933 in adult patients with advanced mesothelioma and other solid tumors.
